Free Trial
NASDAQ:CDIO

Cardio Diagnostics Q2 2025 Earnings Report

Cardio Diagnostics logo
$1.96 -0.04 (-2.00%)
Closing price 10/7/2026 03:59 PM Eastern
Extended Trading
$2.00 +0.04 (+2.24%)
As of 10/7/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cardio Diagnostics EPS Results

Actual EPS
-$0.97
Consensus EPS
-$1.80
Beat/Miss
Beat by +$0.83
One Year Ago EPS
N/A

Cardio Diagnostics Revenue Results

Actual Revenue
$0.01 million
Expected Revenue
$0.08 million
Beat/Miss
Missed by -$65.00 thousand
YoY Revenue Growth
N/A

Cardio Diagnostics Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Cardio Diagnostics' next earnings date is estimated for Friday, November 6, 2026, based on past reporting schedules.

Conference Call Resources

Cardio Diagnostics Earnings Headlines

Don't lose access to this
Ian Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall. The free download walks through strategies for navigating the options market, but the window to claim it is closing soon.tc pixel
See More Cardio Diagnostics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cardio Diagnostics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cardio Diagnostics and other key companies, straight to your email.

About Cardio Diagnostics

Cardio Diagnostics (NASDAQ:CDIO) is a biotechnology and medical technology company focused on the prevention and early detection of cardiovascular disease. The company combines artificial intelligence with genetic and epigenetic data to develop personalized tools intended to help identify cardiovascular risk and support more targeted care.

Its products include Epi+Gen CHD, a blood-based test designed to assess an individual’s risk of developing coronary heart disease, and PrecisionCHD, which is intended to help identify the presence of coronary heart disease. The company’s testing platform is designed to provide physicians with information that may support earlier intervention and individualized prevention strategies.

Founded in 2017, Cardio Diagnostics is headquartered in Chicago and serves the healthcare market through physician-ordered testing and related clinical services. The company was co-founded by Meesha Dogan, who has served as its chief executive officer, and uses its technology to address cardiovascular disease prevention and management.

View Cardio Diagnostics Profile